O	0	12	Differential
O	13	20	effects
O	21	23	of
B-intervention	24	33	metformin
O	34	36	on
O	37	43	breast
O	44	50	cancer
O	51	64	proliferation
O	65	74	according
O	75	77	to
O	78	85	markers
O	86	88	of
O	89	96	insulin
O	97	107	resistance
O	108	111	and
O	112	117	tumor
O	118	125	subtype
O	126	128	in
O	129	130	a
O	131	141	randomized
O	142	153	presurgical
O	154	159	trial
O	159	160	.

O	161	170	Treatment
O	171	173	of
O	174	183	diabetics
O	184	188	with
O	189	198	metformin
O	199	201	is
O	202	212	associated
O	213	217	with
O	218	227	decreased
O	228	234	breast
O	235	241	cancer
O	242	246	risk
O	247	249	in
O	250	263	observational
O	264	271	studies
O	271	272	,
O	273	276	but
O	277	279	it
O	280	287	remains
O	288	295	unclear
O	296	298	if
O	299	303	this
O	304	308	drug
O	309	312	has
O	313	321	clinical
O	322	336	antineoplastic
O	337	345	activity
O	345	346	.

O	347	349	In
O	350	351	a
O	352	358	recent
O	359	370	presurgical
O	371	376	trial
O	376	377	,
O	378	380	we
O	381	386	found
O	387	388	a
O	389	402	heterogeneous
O	403	409	effect
O	410	412	of
O	413	422	metformin
O	423	425	on
O	426	432	breast
O	433	439	cancer
O	440	453	proliferation
O	454	455	(
O	455	457	ki
O	457	458	-
O	458	460	67
O	460	461	)
O	462	471	depending
O	472	476	upon
O	477	484	insulin
O	485	495	resistance
O	496	497	(
O	497	501	HOMA
O	502	507	index
O	507	508	)
O	508	509	.

O	510	514	Here
O	514	515	,
O	516	518	we
O	519	529	determined
O	530	533	the
O	534	546	associations
O	547	549	of
O	550	560	additional
O	561	566	serum
O	567	577	biomarkers
O	578	580	of
O	581	588	insulin
O	589	599	resistance
O	599	600	,
O	601	606	tumor
O	607	614	subtype
O	614	615	,
O	616	619	and
O	620	624	drug
O	625	638	concentration
O	639	643	with
O	644	646	ki
O	646	647	-
O	647	649	67
O	650	658	response
O	659	661	to
O	662	671	metformin
O	671	672	.

B-total-participants	673	676	Two
I-total-participants	676	677	-
I-total-participants	677	684	hundred
B-eligibility	685	688	non
I-eligibility	688	689	-
I-eligibility	689	697	diabetic
I-eligibility	698	703	women
O	704	708	were
O	709	717	randomly
O	718	727	allocated
O	728	730	to
O	731	740	metformin
O	741	742	(
O	742	745	850
O	746	748	mg
O	748	749	/
O	749	752	bid
O	752	753	)
O	754	756	or
B-control	757	764	placebo
O	765	768	for
O	769	770	4
O	771	776	weeks
O	777	782	prior
O	783	785	to
O	786	792	breast
O	793	799	cancer
O	800	807	surgery
O	807	808	.

O	809	812	The
O	813	815	ki
O	815	816	-
O	816	818	67
O	819	827	response
O	828	830	to
O	831	840	metformin
O	841	844	was
O	845	853	assessed
O	854	863	comparing
O	864	868	data
O	869	877	obtained
O	878	882	from
O	883	891	baseline
O	892	898	biopsy
O	899	900	(
O	900	902	ki
O	902	903	-
O	903	905	67
O	906	909	and
O	910	915	tumor
O	916	923	subtype
O	923	924	)
O	925	928	and
O	929	934	serum
O	935	942	markers
O	943	944	(
O	944	948	HOMA
O	949	954	index
O	954	955	,
O	956	957	C
O	957	958	-
O	958	965	peptide
O	965	966	,
O	967	970	IGF
O	970	971	-
O	971	972	I
O	972	973	,
O	974	979	IGFBP
O	979	980	-
O	980	981	1
O	981	982	,
O	983	988	IGFBP
O	988	989	-
O	989	990	3
O	990	991	,
O	992	996	free
O	997	1000	IGF
O	1000	1001	-
O	1001	1002	I
O	1002	1003	,
O	1004	1006	hs
O	1006	1007	-
O	1007	1010	CRP
O	1010	1011	,
O	1012	1023	adiponectin
O	1023	1024	)
O	1025	1029	with
O	1030	1033	the
O	1034	1038	same
O	1039	1051	measurements
O	1052	1054	at
O	1055	1065	definitive
O	1066	1073	surgery
O	1073	1074	.

O	1075	1078	For
O	1079	1087	patients
O	1088	1092	with
O	1093	1094	a
O	1095	1100	blood
O	1101	1107	sample
O	1108	1113	taken
O	1114	1120	within
O	1121	1123	24
O	1124	1125	h
O	1126	1130	from
O	1131	1135	last
O	1136	1140	drug
O	1141	1147	intake
O	1147	1148	,
O	1149	1158	metformin
O	1159	1164	level
O	1165	1168	was
O	1169	1177	measured
O	1177	1178	.

O	1179	1187	Compared
O	1188	1192	with
O	1193	1200	placebo
O	1200	1201	,
O	1202	1211	metformin
O	1212	1225	significantly
O	1226	1235	decreased
B-outcome	1236	1238	ki
I-outcome	1238	1239	-
I-outcome	1239	1241	67
O	1242	1244	in
O	1245	1250	women
O	1251	1255	with
O	1256	1260	HOMA
O	1261	1262	>
O	1263	1264	2
O	1264	1265	.
O	1265	1266	8
O	1266	1267	,
O	1268	1273	those
O	1274	1276	in
O	1277	1280	the
O	1281	1287	lowest
O	1288	1293	IGFBP
O	1293	1294	-
O	1294	1295	1
O	1296	1304	quintile
O	1304	1305	,
O	1306	1311	those
O	1312	1314	in
O	1315	1318	the
O	1319	1326	highest
O	1327	1332	IGFBP
O	1332	1333	-
O	1333	1334	3
O	1335	1343	quartile
O	1343	1344	,
O	1345	1350	those
O	1351	1355	with
O	1356	1359	low
O	1360	1364	free
O	1365	1368	IGF
O	1368	1369	-
O	1369	1370	I
O	1370	1371	,
O	1372	1377	those
O	1378	1380	in
O	1381	1384	the
O	1385	1388	top
O	1389	1391	hs
O	1391	1392	-
O	1392	1395	CRP
O	1396	1403	tertile
O	1403	1404	,
O	1405	1408	and
O	1409	1414	those
O	1415	1419	with
O	1420	1424	HER2
O	1424	1425	-
O	1425	1433	positive
O	1434	1440	tumors
O	1440	1441	.

O	1442	1444	In
O	1445	1450	women
O	1451	1455	with
O	1456	1460	HOMA
O	1461	1466	index
O	1467	1468	>
O	1469	1470	2
O	1470	1471	.
O	1471	1472	8
O	1472	1473	,
B-outcome	1474	1478	drug
I-outcome	1479	1485	levels
O	1486	1490	were
O	1491	1501	positively
O	1502	1512	correlated
O	1513	1517	with
O	1518	1521	the
O	1522	1524	ki
O	1524	1525	-
O	1525	1527	67
O	1528	1536	decrease
O	1536	1537	,
O	1538	1545	whereas
O	1546	1548	no
O	1549	1554	trend
O	1555	1558	was
O	1559	1564	noted
O	1565	1567	in
O	1568	1573	women
O	1574	1578	with
O	1579	1583	HOMA
O	1584	1585	<
O	1586	1587	2
O	1587	1588	.
O	1588	1589	8
O	1590	1591	(
O	1591	1592	p
O	1592	1593	-
O	1593	1604	interaction
O	1605	1606	=
O	1607	1608	0
O	1608	1609	.
O	1609	1611	07
O	1611	1612	)
O	1612	1613	.

O	1614	1616	At
O	1617	1629	conventional
O	1630	1642	antidiabetic
O	1643	1648	doses
O	1648	1649	,
O	1650	1653	the
O	1654	1660	effect
O	1661	1663	of
O	1664	1673	metformin
O	1674	1676	on
O	1677	1682	tumor
O	1683	1685	ki
O	1685	1686	-
O	1686	1688	67
O	1689	1691	of
O	1692	1695	non
O	1695	1696	-
O	1696	1704	diabetic
O	1705	1711	breast
O	1712	1718	cancer
O	1719	1727	patients
O	1728	1734	varies
O	1735	1739	with
O	1740	1744	host
O	1745	1748	and
O	1749	1754	tumor
O	1755	1770	characteristics
O	1770	1771	.

O	1772	1777	These
O	1778	1786	findings
O	1787	1790	are
O	1791	1799	relevant
O	1800	1802	to
O	1803	1809	design
O	1810	1816	breast
O	1817	1823	cancer
O	1824	1834	prevention
O	1835	1838	and
O	1839	1848	treatment
O	1849	1855	trials
O	1856	1860	with
O	1861	1870	metformin
O	1870	1871	.
